Lobaex Tablet 20/80 mg
Rosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
MFDS item code 202006068 · Approved 2020.08.28
This product's status changed to Expired on 2025.08.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of hypertension and heart failure; improvement of dyslipidemia; inhibition of atherosclerosis progression and cardiovascular risk
This medication is used for patients who need to administer both valsartan and rosuvastatin simultaneously. Valsartan is effective in reducing the risks of essential hypertension, heart failure, and post-myocardial infarction mortality. It is particularly prescribed for heart failure patients intolerant to ACE inhibitors. Meanwhile, rosuvastatin helps treat hypercholesterolemia and various forms of dyslipidemia, delays the progression of atherosclerosis, and is used to reduce the risk associated with cardiovascular diseases. This combination of ingredients is effective in the management and prevention of cardiovascular diseases such as hypertension and hyperlipidemia.
This drug should be administered only to adults. The dosage should be individualized for each patient based on the efficacy and tolerability of each component, valsartan and rosuvastatin. ◆ Valsartan 1. Essential hypertension Take with water during a meal or between meals. It is recommended that the drug be taken at the same time each day, if possible (e.g., in the morning). 1) Adults: The recommended dose is 80 mg of valsartan orally once daily, regardless of sex or race. The blood pressure-lowering effect develops gradually within 2 weeks and reaches its maximum effect after 4 weeks. For patients whose blood pressure is not adequately controlled, the dose may be increased to 160 mg once daily or a diuretic may be coadministered. If additional blood pressure reduction is needed, the dose may be increased up to a maximum of 320 mg once daily. 2) Older adults (75 years and older): Initiate treatment with this drug at 40 mg once daily. 3) Patients with renal impairment: (1) Creatinine clearance 20 ∼ 50 mL/min: No dosage adjustment is necessary. (2) Creatinine clearance 10 ∼ 20 mL/min: Initiate treatment with this drug at 40 mg once daily. (3) Creatinine clearance less than 10 mL/min and patients on dialysis: Do not administer this drug. 4) Patients with intravascular volume depletion: In patients with intravascular volume depletion (e.g., patients taking high doses of diuretics whose dose cannot be reduced), initiate treatment with this drug at 40 mg once daily. 5) Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, initiate treatment with this drug at 40 mg once daily; the dose should not exceed 80 mg once daily. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. 2. Heart failure Adults: The recommended initial dose is 40 mg orally twice daily. The dose may be increased to 80 mg or 160 mg per dose. When coadministered with a diuretic, a reduction in the diuretic dose should be considered. The maximum daily dose is 320 mg, given in divided doses. Triple combination therapy with this drug, an ACE inhibitor, and a beta-blocker is not recommended. 3. Reduction of the risk of death after myocardial infarction Adults: Treatment may be initiated within 12 hours of the onset of myocardial infarction. The recommended initial dose is 20 mg twice daily. The dose should then be increased over several weeks, according to the patient's tolerability, to 40 mg, 80 mg, and 160 mg per dose twice daily. Consider dose reduction if symptoms of hypotension or renal failure occur. This drug may also be administered to patients receiving other treatments after myocardial infarction (e.g., thrombolytic agents, acetylsalicylic acid, beta-blockers, and statins). However, coadministration with an ACE inhibitor is not recommended. 4. Patients with renal impairment: No dosage adjustment is necessary when creatinine clearance is 10 mL/min or higher. However, as there is no experience with use in patients with creatinine clearance less than 10 mL/min or in patients on dialysis, do not administer this drug to these patients. 5. Patients with hepatic impairment: In patients with mild or moderate hepatic impairment, the daily dose of this drug should preferably not exceed 80 mg. If administering 80 mg or more daily, consider whether the benefits of treatment outweigh the risks when increasing the dose. Do not administer this drug to patients with severe hepatic impairment, cirrhosis, or cholestasis. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), combined dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this drug and continue it throughout the treatment period. This drug may be taken at any time of day, with or without food. The initial dose is 5 milligrams once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 milligrams once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or longer according to the LDL cholesterol level, treatment goal, and patient response, and may be increased up to a maximum of 20 milligrams once daily. 2. Older adults: No dosage adjustment is necessary. 3. Patients with renal impairment: No dosage adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution is required when administering this drug at 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this drug to patients with active liver disease. 5. Race: As systemic exposure to this drug is increased in Asian patients, the recommended initial dose is 5 milligrams. Administration of the 40 milligrams dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 milligrams. Administration of the 40 milligrams dose is contraindicated in some of these patients. Patients taking valsartan and rosuvastatin concomitantly may switch to this drug (a combination product containing the same amounts of each active ingredient) for convenience.
Children and adolescents under 18 years of age: Safety and efficacy have not been established. Children and adolescents under 18 years of age: Safety and efficacy have not been established.
This medication can cause serious harm to the fetus and newborn if taken during pregnancy, so it must be stopped immediately upon confirmation of pregnancy. It is contraindicated in patients with hypersensitivity to this medication or severe liver disease, renal failure, or myopathy. Women of childbearing potential should use appropriate contraception and those with a low likelihood of pregnancy should be made fully aware of the risks before use. Certain patient groups such as the elderly, patients with hyperkalemia, and liver disease should use this medication cautiously and undergo regular tests for liver function and kidney function during treatment. This medication can cause severe muscle-related adverse reactions like myalgia or myopathy, rarely rhabdomyolysis, so symptoms like myalgia, weakness, or cramps should be reported to a physician immediately. There may be instances of rapid hypotension, and if symptoms of dizziness or fainting occur, immediate consultation with healthcare professionals is necessary. This medication may interact with other antihypertensives, diuretics, potassium-sparing diuretics, so if there are other medications being taken, inform the physician or pharmacist. Interstitial lung disease, liver failure, serious skin reactions have been reported rarely, so if abnormal symptoms occur, stop using the medication and consult healthcare professionals immediately. Pregnant or nursing women should not take this medicine, and if pregnancy is confirmed during use, it should be stopped immediately. Safety and efficacy have not been established in children and adolescents under 18 years of age, so it is advisable not to use it. In case of overdosing, as there is no specific antidote, visit a medical facility immediately for appropriate treatment, as symptoms of decreased blood pressure or altered consciousness may occur. Keep out of reach of children and do not transfer to other containers for safety.
Dyspepsia, nausea, chest discomfort, dizziness, headache, conjunctival hemorrhage, constipation, asthenia, chest pain, facial swelling, peripheral edema, nasopharyngitis, urinary tract infection, contusion, increased serum liver aminotransferase, increased serum creatinine phosphokinase, increased serum potassium, increased gamma-glutamyl transferase, musculoskeletal stiffness, limb pain, sensory loss, anxiety, upper respiratory tract infection, pharyngitis, tonsillitis, spinal canal stenosis, aphasia, oral hemorrhage, vomiting, insulin-dependent diabetes mellitus, diabetes complications, leg fractures, spinal fractures, fractures, skin mass, second-degree atrioventricular block, vestibular neuritis, retinal detachment, undefined skin tumor-like condition, herpes zoster, herniated disc, hemoptysis, sputum disease, bronchitis, sensory abnormalities, hoarseness, gastroesophageal reflux, diverticulitis, gastritis, stomatitis, carpal tunnel syndrome, chills, facial flushing, increased blood sugar, increased triglycerides, neck/shoulder pain, toe fracture, osteomyelitis, skin infection, undefined skin inflammation, localized skin reaction, palpitations, worsening angina, auditory abnormalities, overactive bladder, increased serum creatinine, benign prostatic hyperplasia, laceration, headache, dizziness, viral infection, upper respiratory tract infection, cough, diarrhea, fatigue, rhinitis, sinusitis, abdominal pain, abdominal pain, pharyngitis, arthralgia, drowsiness, atrial fibrillation, constipation, thirst, loss of appetite, malaise, vascular edema, erythema, itching, serum sickness, vasculitis, kidney function impairment, syncope, nosebleed, hepatitis, arrhythmia, interstitial pneumonia, hypoglycemia, shock, loss of consciousness, rhabdomyolysis, agranulocytosis, leukopenia, thrombocytopenia, reduced red blood cell volume, decreased hemoglobin, edema, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, Stevens-Johnson syndrome, eosinophilia with systemic symptoms drug reaction syndrome, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, depression, sleep disorder, interstitial lung disease, sexual dysfunction, gynecomastia, hepatic failure, cognitive impairment, myasthenia gravis, ocular myasthenia gravis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a light-proof container as it is sensitive to light. Furthermore, it should be kept at room temperature between 1°C and 30°C to maintain its efficacy and safety.
Brown round film-coated tablet
30 tablets/box [(10 tablets/PTP) x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Rosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Teragen Etex Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 5.2mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
CombinationRosuvastatin Calcium 10.4mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Dongkwang Pharmaceutical Co., Ltd.
Rosuvastatin Calcium 20.8mg · Valsartan 160mg
Tablet · Prescription medication · Combination
Medika Korea Co., Ltd.
CombinationRosuvastatin Calcium 20.8mg · Valsartan 80mg
Tablet · Prescription medication · Combination
Medica Korea Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.